TY - JOUR T1 - Prognostic Significance of Serum CEA for Non-small Cell Lung Cancer Patients Receiving Stereotactic Body Radiotherapy JF - Anticancer Research JO - Anticancer Res SP - 5161 LP - 5167 VL - 37 IS - 9 AU - TAKASHI SHINTANI AU - YUKINORI MATSUO AU - YUSUKE IIZUKA AU - TAKAMASA MITSUYOSHI AU - TAKASHI MIZOWAKI AU - MASAHIRO HIRAOKA Y1 - 2017/09/01 UR - http://ar.iiarjournals.org/content/37/9/5161.abstract N2 - Background/Aim: To examine the prognostic significance of serum carcinoembryonic antigen (CEA) for stage I non-small cell lung cancer (NSCLC) treated with stereotactic body radiotherapy (SBRT). Patients and Methods: In total, 129 stage I NSCLC patients were analyzed and divided into two groups: CEA-High (CEA>5 ng/ml) and CEA-Low (CEA≤5 ng/ml). Results: Median follow-up time was 38 months. Overall survival was not significantly different between CEA-High (n=47) and CEA-Low (n=82) patients (57% vs. 63% at 3 years; p=0.39), although progression-free survival (PFS) was significantly worse in CEA-High patients (31% vs. 51% at 3 years; p=0.01). Larger tumor size and high CEA level were independent prognostic factors for worse PFS. Failure pattern analysis showed that regional node or distant recurrence was more common in CEA-High patients (47%) than in CEA-Low patients (29%). Conclusion: Patients with CEA-High stage I NSCLC have a higher risk of regional or systemic relapse and should be followed-up carefully. ER -